BSE filing, NSE: BPLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Bharat Parenterals Ltd: key numbers
- Share price
- ₹1,918.70
- Market cap
- ₹1,322 Cr
- Revenue (annual)
- ₹345.4 Cr
- Net profit (annual)
- ₹-8.19 Cr
- P/E (TTM)
- -85.8×Sector 46.1×
- Promoter holding
- 67.20%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Parenterals Ltd
All →Bharat Parenterals Board Meeting Date
Bharat Parenterals will hold a board meeting on October 29, 2026 to consider unaudited standalone and consolidated results. Trading window has been closed since October 1, 2026.
Bharat Parenterals Annual General Meeting
Bharat Parenterals held an EGM via video conferencing on October 23, 2026. Members considered a preferential equity issue and Section 186 investment and guarantee limits.
Bharat Parenterals Business Update
Innoxel Lifesciences, a Bharat Parenterals subsidiary, began U.S. commercial supply of its first CMO product. This adds recurring manufacturing revenue to its existing licensing income.
Bharat Parenterals Other Announcement
Bharat Parenterals Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, as per regulatory requirements.
Bharat Parenterals Annual General Meeting
Bharat Parenterals Limited has issued a notice for an Extraordinary General Meeting (EGM) scheduled for October 23, 2026. Shareholders will consider preferential share issuance and investment approvals.
Bharat Parenterals Fund Raise of ₹139 Cr
Bharat Parenterals approved a preferential issue of 9,12,759 equity shares to non-promoter investors. This fundraise aims to raise Rs. 138.9995 Crore for subsidiary investments.
- Value
- ₹139.0 Cr
Other preferential issue announcements
All →One Global Service Provider Preferential Issue
One Global Service Provider allotted 7,06,068 preferential equity shares to two allottees, for consideration other than cash. Issue value is about Rs.39.54 Crore at the stated prices.
- Value
- ₹39.54 Cr
CCME Global Preferential Issue
CCME Global's Preferential Issue Committee allotted about 15.08 crore equity shares worth Rs 150.84 crore, including shares for cash and for acquiring stakes in CCME UAE and Interlink. Both entities become associate and subsidiary respectively from October 28, 2026.
- Value
- ₹150.8 Cr
Sharp Investments Preferential Issue
Sharp Investment disclosed that its proposed preferential issue is solely to acquire 100% of RLCPL via share swap. The shares carry a nominal Rs.1 face value with no cash consideration.
Avalon Technologies Preferential Issue
Avalon Technologies intimated an EGM on 21 Nov 2026 seeking approval for AoA alterations and a preferential issue of 19,37,808 warrants to Zollner Elektronik AG. The warrants aggregate about ₹425 Crore at ₹2,193.20 each.
- Value
- ₹425.0 Cr
- Execution
- Warrants exercisable for 18 months from allotment
Kuber Udyog Preferential Issue
Kuber Udyog's board approved allotting equity shares and warrants on preferential basis, valued at 276.13 Crore. A share swap acquires 100% of Golden Ikon Fleet Management.
- Value
- ₹276.1 Cr
ACI Infocom Preferential Issue
ACI Infocom allotted 3.2 crore shares and 10 crore warrants to Sanjay & Rupal Mandavia at ₹1.53 each, a ~₹20.20 Crore preferential issue.
- Value
- ₹20.20 Cr